Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...